TIRZEPATIDE USE IN SPECIAL POPULATIONS: ELDERLY, PREGNANT WOMEN, AND ADOLESCENTS WITH TYPE 2 DIABETES

T2D is a rapidly increasing disease affecting people of all ages globally and becoming more profound among elderly, pregnant females as well as teenagers. It has been noted that tripeptide, a dual agonist of GLP-1 and GIP receptors, has the potential to translate the concepts of GI physiology into therapeutic gains in the field of glycemic management and obesity. However, the effectiveness of the medication in such populations has not been researched much. In this systematic review, how safe and effective Tirzepatide is in Costello's elderly, Pregnant, and adolescent patients with T2D is to be examined in comparison to the traditional diabetes medication. A thorough search process was performed using the online database to identify randomised control trials, cohort studies and observation studies of Tirzepatide in the unique population. These were the variations of glycosylated haemoglobin level, weight and the number of adverse effects, respectively. In order to account for heterography, a meta-analysis was conducted, with most analyses being based on random-effect models. These studies demonstrated that tripeptide achieved a significant HbA1c decrease from 1.2% to 2.4%, as well as weight loss of 5% to 12% in all three populations. Among the side effects observed in patients of this age group, Hypoglycemia and gastrointestinal discomfort were more frequent. Pregnant women had sound maternal effects, and no adverse fetal effects were observed. Teenagers reaped considerable improvements in glycemic control and BMI; they reported side effects in the form of mild discomfort in their stomachs. It can be concluded that tripeptide provides a good profile for managing T2D in special populations. However, the potential adverse effects should be considered while using it, including use in pregnant females and adolescents. Further prospective long-term and large-scale trials in women and various racial populations are needed to determine the safety of the drug in these categories. It is, therefore, advisable that an individual develop a treatment plan that suits the extent of their baldness and receive follow-up tests that show the degree of success.